A project with an up-front cost att Pharmaceutical Corporation (NP subsequent cash flows are critically under development is approved by competitive product upon the comp and cash flows, but if the competitive product is approved, that There is a 75% chance that the compet expected cash flows will be $500 at the end of each up-front cost at t 0 of S1500 is being considered by Nationwide oration (NPC). (All dollars in this problem are in thousands.) The projects sare critically dependent on whether a competitor's product that is now approved by the Food and Drug Administration. If the FDA rejects the upon the completion of its development. NPC's product will have high sales duct is approved, that will negatively impact NPC. nance that the competitive product will be rejected, in which case NPC'S Hows will be $500 at the end of each of the next seven years (t-1 to 7). There is a 70 chance that the competitor's product will be approved, in which case the expected Ilows will be only $25 at the end of each of the next seven years (t = 1 to 1). N only sometime later whether the competitor's product is going to be approved. d of each of the next seven years (t = 1 to 7). NPC will know NPC will proceed with the investment today to take advantage of the untapped market potential and at the end of the project's life, after finding out about the FDA's decision about the demand of competitor's product, they will decide whether or not to renew the patent and rerun the project. The project rerun's up-front cost (at t= 7) will remain at $1,500, and the subsequent cash flows will remain unchanged and will be received for seven additional years (t 8 ... 14). They will only rerun the project if the rerun of the project adds value. Assuming that all cash flows are discounted at 10%, what are the NPV and CV of the project with and without the growth option? Wlo option EWPV) - 356.06 CV=2.81 with growth option ECUP) = 715.63 Cu = 1.69 A project with an up-front cost att 0 of $1500 is being considered by Nationwide maceutical Corporation (NPC). (All dollars in this problem are in thousands.) The project subsequent cash flows are critically dependent on whether a competitor's product that is now under development is approved by the Food and Drug Administration. If the FDA rejects the petitive product upon the completion of its development, NPC's product will have high sal and cash flows, but if the competitive product is approved, that will negatively impact NPC. There is a 75% chance that the competitive product will be rejected, in which case NPC'S expected cash flows will be $500 at the end of each of the next seven years (t = 1 to 7). There i 25% chance that the competitor's product will be approved, in which case the expected cash llows will be only $25 at the end of each of the next seven years (t = 1 to 7). NPC will know only sometime later whether the competitor's product is going to be approved. NPC will proceed with the investment today to take advantage of the untapped market potentia and at the end of the project's life, after finding out about the FDA's decision about the demang for competitor's product, they will decide whether or not to renew the patent and rerun the project. The project rerun's up-front cost (at t = 7) will remain at $1,500, and the subsequent cash flows will remain unchanged and will be received for seven additional years (t=8... 14). They will only rerun the project if the rerun of the project adds value. Assuming that all cash flows are discounted at 10%, what are the NPV and CV of the project with and without the growth option? Wlo option EWPU) = 356.06 CV=2.81 with growth option ECOPY) = 715.63 Cu=1.69